Korea United Pharm. Inc.
Clinical trials sponsored by Korea United Pharm. Inc., explained in plain language.
A South Korean pharmaceutical company producing generic and specialty drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo pill for blood pressure and cholesterol moves to safety testing Results expected Sep 2026 (estimated)
-
Can a new pill beat acid reflux? two drugs go Head-to-Head
Disease control Not yet recruitingThis phase 1 trial tests two experimental oral drugs, UI059 and UIC202201, in healthy adult volunteers to see how safe they are and how well they control stomach acid. Each participant takes one drug daily for a week, then switches to the other after a break. The goal is to compa…
Phase 1 • Sponsor: Korea United Pharm. Inc. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Could a single pill replace three diabetes drugs? early study begins
Knowledge-focused Not yet recruitingThis early-stage trial tests a new experimental pill called UI087, which combines three diabetes drugs into one. Researchers want to see if it is safe and how the body processes it compared to taking the three drugs separately. The study involves 44 healthy adults and is not yet …
Phase 1 • Sponsor: Korea United Pharm. Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC